Highlights of the Pananemia National meeting of the Italian Southern Oncological Group (GOIM): pharmacological and molecular treatment of cancer-induced anemia

Authors: Addeo, Raffaele; Caraglia, Michele; Del Prete, Salvatore

Source: Expert Opinion on Pharmacotherapy, Volume 10, Number 6, April 2009 , pp. 1089-1093(5)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Anemia commonly occurs in cancer patients and results in symptoms such as fatigue which have a profound impact on quality of life. Anemia is also associated with poor treatment outcome and overall survival. Several studies in patients with solid tumors have shown that erythropoiesis-stimulating agents (ESA), such as recombinant erythropoietins, effectively increase hemoglobin levels and reduce the need for emergency blood transfusions, regardless of the type of concomitantly administered chemotherapy. This Italian meeting, sponsored by the Italian Southern Oncological Group (GOIM) and Southern Pananemia Study Group, focused on various aspects of cancer-related anemia and its treatment options.

Keywords: cancer-related anemia; erythropoietin beta; iron; non-erythropoietin ESAs; prolyl-hydroxylase inhibitors; quality of life

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14656560902868159

Publication date: 2009-04-01

More about this publication?